Dr. Sarah Helen Sofka, MD

Dr. Sofka practices at Rockefeller Neuroscience Institute - Neurology - HOPD in Morgantown, West Virginia.

Dr. Sofka's NPI, 1003088550, was assigned on March 25, 2008. Dr. Sofka graduated from West Virginia University School of Medicine in 2008. Dr. Sofka holds West Virginia license 23980.

Dr. Sofka's primary practice is Rockefeller Neuroscience Institute - Neurology - HOPD, at 33 Medical Center Dr, Morgantown, WV 26505.

Dr. Sofka's primary practice is Rockefeller Neuroscience Institute - Neurology - HOPD in Morgantown, West Virginia. Dr. Sofka is also affiliated with J.W. Ruby Memorial Hospital. The medical group on file is University Health Associates. Dmand AI also links Dr. Sofka to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sofka practices, 3 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Sofka's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Sofka is board certified in internal medicine by the American Board of Internal Medicine. Dr. Sofka is licensed in West Virginia.

CMS data shows 248 Medicare services from Dr. Sofka across 7 procedure codes in 2024, for 96 Medicare patients. Medicare paid $19,785 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 96 Medicare patients who saw Dr. Sofka in 2024. The largest group is 65 to 74, with 44 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 25% are also on Medicaid. Their average risk score is 1.79, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sofka's median patient age at 68, with 43% women.

In 2024, Dr. Sofka wrote 184 Medicare Part D claims for 37 patients. 85% of them were for generic drugs. CMS names the drug for 52 of them, across 4 drugs with 11 or more claims each, at $348 in total drug cost. In 2023, CMS named 75 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Sofka for performance year 2024, reported through an alternative payment model (APM). Dr. Sofka accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 18 papers to Dr. Sofka, published from 2013 to 2024. 2021 was the busiest year, with 3. The most frequent topics are COVID-19, Internship and Residency and SARS-CoV-2. Dr. Sofka has published most often in J Grad Med Educ. Dr. Sofka's most frequent co-authors are Nathan Meyer Lerfald, MD, Josephine L. Reece, MD and Dhairya A. Lakhani, MD.

CMS Open Payments shows 1 general payment to Dr. Sofka from 1 drug or device company in 2023. Speaker and faculty fees make up the largest share, 100% of the total. Bausch Health Americas, Inc. paid the most, $1,500.

Dr. Sofka graduated from West Virginia University School of Medicine in 2008.